培美曲塞联合奥沙利铂治疗晚期非小细胞肺癌的临床观察

Observation on the clinical efficiency of pemetrexed combined with oxaliplatin in the treatment of advanced non-small cell lung cancer

目的:观察培美曲塞联合奥沙利铂治疗晚期非小细胞肺癌的临床疗效。方法:收集晚期非小细胞肺癌患者,随机分为研究组与对照组,研究组应用培美曲塞联合奥沙利铂化疗,而对照组应用吉西他滨联合奥沙利铂化疗,两个疗程后,比较两组临床疗效、生活质量、CEA及CA125水平变化、化疗不良反应情况。结果:研究组临床有效率虽高于对照组,但两组差异无统计学意义(P>0.05);研究组生活质量提高明显优于对照组(P<0.05);治疗后2组患者CEA及CA125水平均下降,且研究组较对照组下降更明显(P<0.05);而研究组并未增加化疗毒副反应。结论:培美曲塞联合奥沙利铂治疗晚期非小细胞肺癌疗效肯定,在某些方面优于吉西他滨,是一安全有效的化疗选择。

OBJECTIVE To study the clinical efficiency of pemetrexed combined with oxaliplatin in the treatment of advanced nowsmall cell lung cancer. METHODS Advanced non-small cell lung cancer patients were randomly divided into study group and control group. The study group received pemetrexed combined with oxaliplatin chemotherapy, while the control group had gemcitabine and oxaliplatin chemotherapy. The two groups were compared of the clinical efficiency, quality of life, CEA and CA125 level changes, chemotherapy toxicity after two courses. RESULTS Although the clinical efficiency of study group was higher than that of the control group, but there were no significant changes （P〉0. 05）. The study group improved more than the control group in quality of life （P〈0. 05）. After treatment, the level of CEA and CA125 all decreased, and the study group decreased more significantly than the control group （P〈0.05）. While in the study group the toxic reaction of chemotherapy was no more than that in the control group. CONCLUSION Pemetrexed combined with oxalipiatin in the treatment of advanced non-small cell lung cancer is effective and superior to gemcitabine. It is a safe and effective chemotherapy options.